COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system

被引:313
作者
Bech-Otschir, D
Kraft, R
Huang, XH
Henklein, P
Kapelari, B
Pollmann, C
Dubiel, W
机构
[1] Humboldt Univ, Fac Med Charite, Dept Surg, Div Mol Biol, D-10117 Berlin, Germany
[2] Humboldt Univ, Fac Med Charite, Inst Biochem, D-10117 Berlin, Germany
[3] Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany
[4] Max Planck Inst Biochem, Dept Biol Struct, D-82152 Martinsried, Germany
关键词
COP9; signalosome; Jab1; Mdm2; proteasome; ubiquitin;
D O I
10.1093/emboj/20.7.1630
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In higher eukaryotic cells, the p53 protein is degraded by the ubiquitin-26S proteasome system mediated by Mdm2 or the human papilloma virus E6 protein. Here we show that COP9 signalosome (CSN)-specific phosphorylation targets human p53 to ubiquitin-26S proteasome-dependent degradation. As visualized by electron microscopy, p53 binds with high affinity to the native CSN complex. p53 interacts via its N-terminus with CSN subunit 5/Jab1 as shown by far-western and pull-down assays. The CSN-specific phosphorylation sites were mapped to the core domain of p53 including Thr155. A phosphorylated peptide, Delta p53(145-164), specifically inhibits CSN-mediated phosphorylation and p53 degradation. Curcumin, a CSN kinase inhibitor, blocks E6-dependent p53 degradation in reticulocyte lysates. Mutation of Thr155 to valine is sufficient to stabilize p53 against E6-dependent degradation in reticulocyte lysates and to reduce binding to Mdm2. The p53T155V mutant accumulates in both HeLa and HL 60 cells and exhibits a mutant (PAb 240+) conformation. It induces the cyclin-dependent inhibitor p21, In HeLa and MCF-7 cells, inhibition of CSN kinase by curcumin or Delta p53(145-164) results in accumulation of endogenous p53.
引用
收藏
页码:1630 / 1639
页数:10
相关论文
共 44 条
[1]   Curcumin is an in vivo inhibitor of angiogenesis [J].
Arbiser, JL ;
Klauber, N ;
Rohan, R ;
van Leeuwen, R ;
Huang, MT ;
Fisher, C ;
Flynn, E ;
Byers, HR .
MOLECULAR MEDICINE, 1998, 4 (06) :376-383
[2]   Enhanced phosphorylation of p53 by ATN in response to DNA damage [J].
Banin, S ;
Moyal, L ;
Shieh, SY ;
Taya, Y ;
Anderson, CW ;
Chessa, L ;
Smorodinsky, NI ;
Prives, C ;
Reiss, Y ;
Shiloh, Y ;
Ziv, Y .
SCIENCE, 1998, 281 (5383) :1674-1677
[3]   Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells [J].
BeerRomero, P ;
Glass, S ;
Rolfe, M .
ONCOGENE, 1997, 14 (05) :595-602
[4]   Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity [J].
Bianchi, E ;
Denti, S ;
Granata, A ;
Bossi, G ;
Geginat, J ;
Villa, A ;
Rogge, L ;
Pardi, R .
NATURE, 2000, 404 (6778) :617-+
[5]   Cell cycle - Piecing together the p53 puzzle [J].
Carr, AM .
SCIENCE, 2000, 287 (5459) :1765-1766
[6]   JAB1 interacts with both the progesterone receptor and SRC-1 [J].
Chauchereau, A ;
Georgiakaki, M ;
Perrin-Wolff, M ;
Milgrom, E ;
Loosfelt, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) :8540-8548
[7]  
Chehab NH, 2000, GENE DEV, V14, P278
[8]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[9]   A new group of conserved coactivators that increase the specificity of AP-1 transcription factors [J].
Claret, FX ;
Hibi, M ;
Dhut, S ;
Toda, T ;
Karin, M .
NATURE, 1996, 383 (6599) :453-457
[10]   The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators [J].
Dechend, R ;
Hirano, F ;
Lehmann, K ;
Heissmeyer, V ;
Ansieau, S ;
Wulczyn, FG ;
Scheidereit, C ;
Leutz, A .
ONCOGENE, 1999, 18 (22) :3316-3323